Repare Therapeutics Inc. Stock Price, News & Analysis

Repare Therapeutics (RPTX) reported positive results from its MYTHIC Phase 1 gynecologic expansion trial combining lunresertib and camonsertib (Lunre+Camo). The trial showed a 25.9% overall response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. Nearly half of patients maintained progression-free survival at 24 weeks.

The study included heavily pretreated patients, with many receiving the treatment as fourth line or beyond. In endometrial cancer patients, 100% had prior platinum therapy and 77.8% received immune checkpoint inhibitors. For ovarian cancer patients, all were platinum-resistant or ineligible, with 45.8% having received prior PARP inhibitors.

The company plans to initiate a registrational Phase 3 trial for endometrial cancer in second half of 2025.

Repare Therapeutics (Nasdaq: RPTX) announced a webcast presentation of data from its Phase 1 MYTHIC clinical trial on December 12, 2024. The trial evaluates the combination of lunresertib and camonsertib at the recommended Phase 2 dose in patients with platinum-resistant ovarian and endometrial cancers with specific genetic markers (CCNE1 amplification or FBXW7 or PPP2R1A mutations).

The presentation will feature Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center, alongside Repare's executive management team. The event will be accessible via conference call and live video webcast through the company's investor relations website.

Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly demonstrating prolonged progression-free survival in ATM-mutated non-small cell lung cancer patients. Recent Phase 1 results combining camonsertib with radiotherapy showed complete responses in patients with ATM-altered tumors. CTEP will focus on combination studies involving camonsertib with radiation therapy and translational studies for biomarker identification.

Repare Therapeutics (RPTX) reported Q3 2024 financial results and clinical updates. The company ended Q3 with $179.4 million in cash and equivalents, expected to fund operations into H2 2026. Q3 net loss widened to $34.4 million ($0.81/share) from $18.9 million in Q3 2023. The company reduced workforce by 25% in August 2024 to focus on clinical-stage programs.

Key pipeline updates include upcoming MYTHIC trial data in December 2024, positive safety data presentation at EORTC-NCI-AACR, and first patient dosed in POLAR trial. The company plans to begin a registrational trial in 2025 for its lunresertib-camonsertib combination therapy in gynecologic cancers.

Repare Therapeutics (RPTX) presented updated data from its Phase 1 MYTHIC clinical trial, demonstrating successful management of anemia through an individualized dosing schedule of lunresertib (PKMYT1 inhibitor) and camonsertib (ATR inhibitor) combination therapy. The new schedule significantly reduced Grade 3 anemia rates to 22.6% from 51.4%, while maintaining clinical benefits. Key improvements include reduced red blood cell transfusions (13% vs 43%), fewer dose interruptions (13% vs 23%), and lower dose reductions (6% vs 17%). The trial showed no thrombocytopenia and no serious neutropenia, with maintained antitumor activity and radiographic regressions.

Repare Therapeutics (Nasdaq: RPTX) has dosed the first patient in its Phase 1 POLAR clinical trial for RP-3467, a Polθ ATPase inhibitor. The trial will evaluate RP-3467 alone and in combination with the PARP inhibitor olaparib. RP-3467 is Repare's fourth clinical program and has shown promising preclinical results, including complete and durable tumor regressions when combined with olaparib, without additional toxicities.

The POLAR trial (NCT06560632) aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467. It will enroll approximately 52 patients with advanced solid tumors, including ovarian, breast, prostate, and pancreatic cancers. The study's primary objectives are to evaluate safety and tolerability, and determine a recommended Phase 2 dose for the combination therapy.

Repare Therapeutics (Nasdaq: RPTX) presented Phase 1 data at the ASTRO Annual Meeting, showcasing the potential of camonsertib, an oral ATR inhibitor, combined with palliative radiation for treating metastatic tumors with ATM mutations. The study enrolled 17 patients, 12 with pathogenic ATM mutations and 5 with variants of unknown significance (VUS).

Key findings include:

• Recommended Phase 2 dose: 160 mg camonsertib once-daily before 4Gy radiation on days 1-5
• At 2 months: Pathogenic group showed 2 complete responses (CR), 5 partial responses (PR), 4 stable disease (SD); VUS group had 1 PR, 4 SD
• At 6 months (9 evaluable patients): Pathogenic group reported 2 CR, 4 PR, 1 SD; VUS group had 1 SD, 1 progressive disease

The results suggest potential radiosensitization and higher clinical benefit in patients with pathogenic ATM mutations compared to those with VUS.

Repare Therapeutics presented new data at AACR's Ovarian Cancer Research Symposium, highlighting the impact of FBXW7, PPP2R1A, and CCNE1 alterations in metastatic ovarian and endometrial cancers. The analysis of approximately 2,000 patients revealed:

1. Ovarian cancer: Patients with these biomarkers (Lunre BM+) had a median overall survival (mOS) of 26 months compared to 36 months for those without (Lunre BM-), representing a 28% decrease in mOS.

2. Endometrial cancer: Lunre BM+ patients had an mOS of 30 months versus 41 months for Lunre BM- patients, a 27% decrease in mOS.

These findings underscore the need for innovative treatments for patients with these biomarkers. Repare's Phase 1 MYTHIC trial is studying the combination of lunresertib and camonsertib in patients with these biomarkers, with data expected in Q4 2024.

Repare Therapeutics (Nasdaq: RPTX) will present new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial at the ESMO Congress 2024 in Barcelona. The trial evaluates camonsertib monotherapy in patients with advanced solid tumors harboring ATM loss-of-function. TRESR (NCT04497116) is a first-in-human, multi-center, open-label study designed to establish the recommended Phase 2 dose and schedule, while assessing safety, pharmacokinetics, and preliminary anti-tumor activity. Dr. Benedito A. Carneiro from Brown University will deliver an oral presentation on September 14, sharing insights on camonsertib's performance in treating these specific cancer types.